AI-powered search
AI-powered search

On-Demand CME Videos

'5 in 5' Tips on Managing the 'Itch-Scratch Cycle' of Prurigo Nodularis with Biologics


This 10-minute microlearning discussion is designed to provide "5 practical tips" on Prurigo Nodularis management that you can incorporate into clinical practice. Learn through short bursts of information focused on clinical diagnosis, disease burden, the role of biologics, patient-centered management and treatment timing.

This activity is supported by educational grants from Galderma, and Sanofi and Regeneron Pharmaceuticals, Inc.


In order to ensure educational material is relevant, educational materials will expire after a certain time period. This course will be available for the following dates:

Release Date:

March 8, 2024

Expiration Date:

March 10, 2025

Learning Objectives

At the completion of this activity, participants should be better able to:

  • Describe the impact of prurigo nodularis (PN) on patient quality of life, including sleep quality and mental health

  • Review efficacy and safety data for approved and emerging biologics to manage PN

  • Discuss patient-centered strategies for integrating new and emerging biologics for PN into clinical care

Intended Audience

This activity has been designed for dermatologists, dermatology physician assistants, dermatology nurse practitioners, and other providers involved in the care of patients.

Raj Chovatiya, MD, PhD, MSCI

Clinical Associate Professor, Rosalind Franklin University Chicago Medical School Founder and Director, Center for Medical Dermatology and Immunology Research 
Chicago, IL

Sarina Elmariah, MD, PhD, MPH

Director, UCSF Itch and Neurosensory Center 
Associate Professor of Dermatology
University of California San Francisco​ 
San Francisco, CA​

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of University of Nevada, Reno School of Medicine and CMEsquared. The University of Nevada, Reno School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The University of Nevada, Reno School of Medicine designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures & Disclaimers

Disclosures are as follows:

Raj Chovatiya, MD, PhD, MSCI

Consultant: AbbVie, Arcutis, Arena, Argenx, Beiersdorf, Bristol Myers Squibb, Dermavant, Eli Lilly and Company, EPI Health, Incyte, LEO Pharma, L’Oréal, National Eczema Association, Pfizer Inc., Regeneron, Sanofi, and UCB

Speakers’ Bureau or Honoraria: AbbVie, Arcutis, Dermavant, Eli Lilly and Company, Incyte, LEO Pharma, Pfizer Inc., Regeneron, Sanofi, and UCB

Sarina B. Elmariah, MD, PhD, MPH

Advisory Board: Bellus Health, Galderma, Pfizer, Sanofi Regeneron, Trevi Therapeutics

Speaker's Bureau: Eli Lilly, Pfizer

Ownership Interest: Frontier Bio

The University of Nevada, Reno School of Medicine discloses that all relevant conflicts have been satisfactorily mitigated.


The leading solutions platform for dermatology professionals to elevate patient care.

Contact Us


Subscribe now

Enter your email to get the latest updates.

© 2024 dermsquared | All Rights Reserved